Chinese Agencies’ Agreement Could Halve Approval Time For U.S. Devices
This article was originally published in The Gray Sheet
Executive Summary
Chinese approval time for imported medical devices could be cut in half under an agreement to reduce redundancies between the country's Administration of Quality Supervision, Inspection and Quarantine (AQSIQ) and its State Food and Drug Administration (SFDA)
You may also be interested in...
Health Care Reform In China: A Talk With Political Expert Yanzhong Huang
As China debates reforms to its health care system, a key question is whether it will favor a government-led or market-led approach to health care, according to Yanzhong Huang, an expert on Chinese politics and director of the Center for Global Health Studies at Seton Hall University
Health Care Reform In China: A Talk With Political Expert Yanzhong Huang
As China debates reforms to its health care system, a key question is whether it will favor a government-led or market-led approach to health care, according to Yanzhong Huang, an expert on Chinese politics and director of the Center for Global Health Studies at Seton Hall University
Clarification on China agencies’ redundancy reduction effort
Plan for China's Administration of Quality Supervision, Inspection and Quarantine and its State Food and Drug Administration to reduce redundancies between them by requiring only one test, one report, one fee and one factory inspection, applies to eight specific device types (1"The Gray Sheet" Sept. 22, 2008, p. 8). Other device types were not affected by the problem. The eight types include: X-ray systems, hemodialysis systems, extracorporeal circulation tubes for blood purification, hollow-fiber dialyzers, heart-lung machines, electrocardiographs, pacemakers and condoms